Biotech establishing a Toronto-based team to advance the discovery of rejuvenation gene targets through AI-powered virtual cell technology.
Shift Bioscience, a biotech firm specializing in AI-driven virtual cell technology to combat age-related diseases, has announced the establishment of a new team and facilities in Toronto, Canada. This strategic expansion aims to accelerate the development of the company’s platform dedicated to identifying rejuvenation gene targets, and the Toronto team will be led by the Head of Machine Learning, Lucas Camillo, with Professor Bo Wang of the University of Toronto appointed as Senior Advisor.
Longevity.Technology: Shift Bioscience’s expansion into North America, particularly Toronto, signifies a key advancement for both the company and the broader longevity biotechnology sector. North America is a leading hub for AI and machine learning scientists, and this expansion will allow Shift Bioscience to tap into this talent pool, strengthening their capabilities in AI-powered virtual cell technology, accelerating the identification of novel therapies for age-related diseases and enabling Shift to further strengthen its intellectual property portfolio – something which is crucial in the competitive biotech industry.
This move, following Shift’s $16 million seed funding round last year, demonstrates growing investor confidence in this sort of research; Shift’s AI-powered virtual cell platform has already identified novel transcription factors that can rejuvenate aged human fibroblasts without activating tumor-inducing pathways, and the expansion could accelerate such discoveries, potentially leading to safer and more effective antiaging therapies. Being in a major biotech hub like Toronto opens up possibilities for collaborations with other research institutions and companies, potentially accelerating progress in the field.
Shift Bioscience’s virtual cell platform leverages AI to simulate cellular processes, enabling the uncation of gene sets capable of safely rejuvenating cells. This approach addresses the limitations associated with traditional cellular reprogramming techniques, particularly the tumorigenic risks posed by Yamanaka factors. By focusing on gene targets that do not induce pluripotency, the company aims to develop therapies that reverse cellular aging without compromising safety.
Leading the Toronto team, Lucas Camillo will be leveraging the team’s expertise to explore novel capabilities for the platform, and identify new rejuvenation gene targets. Camillo expressed his enthusiasm for the venture. “North America boasts some of the world’s most successful AI companies, and the importance of being able to access the region’s extensive talent pool cannot be understated,” he said.
“I look forward to working closely with Bo to build out a world-class team of machine learning scientists, and to continue development of our virtual cell platform as an invaluable tool to unlock new gene targets that could potentially treat even the most debilitating of age-related diseases.”
Professor Bo Wang, appointed as Senior Advisor, is an Assistant Professor at the University of Toronto and serves as Chief AI Scientist for the University Health Network, Canada’s leading research hospital. His expertise lies in developing machine learning algorithms for applications ranging from personalized patient care to cell simulation, and his involvement is anticipated to provide strategic guidance in refining Shift Bioscience’s virtual cell technology.
“Embracing the transformative power of AI is crucial to developing innovative treatments that can transform patient care,” he said. “Shift Bioscience’s virtual cell technology is doing just that, unlocking new gene targets that have the potential to address the growing burden of age-related diseases. I’m pleased to be joining the team, and to draw on my experience in cell simulation to accelerate the development of the Company’s powerful virtual cell platform.”
